In 2025, Vertex Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
However, Vertex Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 12,296a | 8,976a | 8,311a | |
Total Scope 2 | ||||
Market-Based | 1,278a | 3,930a | 4,888a | |
Location-Based | 15,443a | N/A | 14,405b | |
Total Scope 3 | 579,649a | 551,647a | 474,129a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 1.0246a | 0.8145a | 0.8421a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Vertex Pharmaceuticals amounted to 27,739 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Vertex Pharmaceuticals increased by 114.93%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of Vertex Pharmaceuticals were 12,296 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Vertex Pharmaceuticals's Scope 1 emissions have increased by 110.76%, reflecting a rising long-term trend in Scope 1 emissions over time.ac
Compared to the previous year (2024), Vertex Pharmaceuticals's Scope 1 emissions increased by 36.99%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2025, Vertex Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 1,278 tCO₂e using the market-based method and 15,443 tCO₂e using the location-based method.a
In 2025, Vertex Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2025, Vertex Pharmaceuticals reported 579,649 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Vertex Pharmaceuticals includes a breakdown across 0 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2025, Vertex Pharmaceuticals reported total Scope 3 emissions of 579,649 metric tons of CO₂ equivalent (tCO₂e).a
Compared to the previous year (2024), Vertex Pharmaceuticals's Scope 3 emissions remained relatively stable, indicating that Vertex Pharmaceuticals's emissions have plateaued with no significant change in its value chain footprint.a
In 2025, Vertex Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 12,296 tCO₂e and total revenues of USD 12,001 millions. This translates into an emissions intensity of 1.02 tCO₂e per millions USD.a
In 2025, Vertex Pharmaceuticals reported a Scope 1 emissions intensity of 1.02 tCO₂e per millions USD. Compared to the peer group median of 2.64, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, Vertex Pharmaceuticals ranked 6 out of 21 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Vertex Pharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2025, Vertex Pharmaceuticals reported a total carbon footprint of 607,388 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 7.59% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Vertex Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 95.43% of the company's total carbon footprint, followed by Scope 2 emissions at 2.54%.a